Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli

Key Takeaways MIRM finishes enrollment in the EXPAND study on Livmarli for additional settings of cholestatic pruritus.MIRM expects Q4 2026 top-line data to support potential Livmarli label expansion into new indications.Livmarli drives growth, with 2025 sales up 68.8% Y/Y and continued demand boosting Mirum's revenues.Mirum Pharmaceuticals (MIRM) announced that it has completed enrollment in the phase III EXPAND study, which evaluated Livmarli (maralixibat) for treating cholestatic pruritus in patients age ...